Similarly, CRISPR has been evaluated to increase chemosensitivity in breast cancer by inactivating or down-regulating the MDR1 gene (also known as ABCB1) that significantly increased the doxorubicin cytotoxicity in resistant chemotherapy breast cancer cells. Here, ABCB1 is linked to breast carcinoma.